Literature DB >> 24151327

Effect of medical oncologists' attitudes on accrual to clinical trials in a community setting.

Carol P Somkin1, Lynn Ackerson, Gail Husson, Vicky Gomez, Tatjana Kolevska, Desiree Goldstein, Louis Fehrenbacher.   

Abstract

PURPOSE: Oncology clinical trials (OCTs) are crucial in evaluating new cancer treatments, but only 2% to 3% of US adult patients with cancer enter OCTs. This study assessed barriers to participation in clinical trials among oncologists in a large integrated health care delivery system with an active clinical trials program. Although many studies have identified major physician barriers to enrollment, few have examined how these barriers affect actual trial accrual.
METHODS: Using information from a mailed survey, we examined the effect of oncologists' attitudes, beliefs, experiences, sociodemographic factors, and practice characteristics on clinical trial accrual in the 2 years following the survey. We identified relationships between these variables and subsequent clinical trial accrual using correlations and mixed effects models.
RESULTS: A construct combining questions that assessed oncologist attitudes, beliefs, and experiences substantially influenced OCT enrollment (r = .51; P < .0001). This construct included awareness of open clinical trials and specific eligible patients, as well as the practice of initiating a discussion about OCTs with most eligible patients. This broad concept of awareness had the greatest correlation with enrollment and mediated the effect on enrollment of other values and beliefs, such as welcoming a patient's initiation of a trial discussion and valuing the support of research nurses and coordinators.
CONCLUSION: Even in a health care setting with an active clinical trials program, substantial research personnel, infrastructure support, and widespread access to trials among oncologists and patients, oncologists' participation remains quite variable. Oncologist values, beliefs, and awareness of clinical trials play an important role in OCT accrual.

Entities:  

Mesh:

Year:  2013        PMID: 24151327      PMCID: PMC5706122          DOI: 10.1200/JOP.2013.001120

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  33 in total

1.  Increasing participation of physicians and patients from underrepresented racial and ethnic groups in National Cancer Institute-sponsored clinical trials.

Authors:  Michaele C Christian; Edward L Trimble
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-03       Impact factor: 4.254

2.  The study of accrual to clinical trials: can we learn from studying who enters our studies?

Authors:  Otis W Brawley
Journal:  J Clin Oncol       Date:  2004-04-13       Impact factor: 44.544

3.  The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer.

Authors:  R Kaas; A A M Hart; E J Th Rutgers
Journal:  Breast       Date:  2005-08       Impact factor: 4.380

4.  Provider roles in the recruitment of underrepresented populations to cancer clinical trials.

Authors:  Mollie W Howerton; M Chris Gibbons; Charles R Baffi; Tiffany L Gary; Gabriel Y Lai; Shari Bolen; Jon Tilburt; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass; Jean G Ford
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

5.  Looking beyond translation--integrating clinical research with medical practice.

Authors:  Annetine C Gelijns; Sherine E Gabriel
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

6.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.

Authors:  Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

7.  Physician-related factors involved in patient decisions to enroll onto cancer clinical trials.

Authors:  Robert L Comis; Jon D Miller; Diane D Colaizzi; Linda G Kimmel
Journal:  J Oncol Pract       Date:  2009-03       Impact factor: 3.840

8.  Accrual to cancer clinical trials in the era of molecular medicine.

Authors:  Richard L Schilsky
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

9.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  Barriers to clinical trial participation by older women with breast cancer.

Authors:  M Margaret Kemeny; Bercedis L Peterson; Alice B Kornblith; Hyman B Muss; Judith Wheeler; Ellis Levine; Nancy Bartlett; Gini Fleming; Harvey J Cohen
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544

View more
  16 in total

1.  Conceptual Model for Accrual to Cancer Clinical Trials.

Authors:  Simon J Craddock Lee; Caitlin C Murphy; Ann M Geiger; David E Gerber; John V Cox; Rasmi Nair; Celette Sugg Skinner
Journal:  J Clin Oncol       Date:  2019-06-05       Impact factor: 44.544

2.  Priorities for Rural Lymphoma Survivors: A Qualitative Study.

Authors:  Lillian Chen; Jackelyn B Payne; Kaylin V Dance; Conner B Imbody; Cathy D Ho; Amy A Ayers; Christopher R Flowers
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-10-19

3.  Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors.

Authors:  Monica Khunger; Sagar Rakshit; Adrian V Hernandez; Vinay Pasupuleti; Kate Glass; Matthew D Galsky; Petros Grivas
Journal:  Oncologist       Date:  2018-08-01

4.  Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment.

Authors:  Lena E Winestone; Kelly D Getz; Pooja Rao; Yimei Li; Matt Hall; Yuan-Shung V Huang; Alix E Seif; Brian T Fisher; Richard Aplenc
Journal:  Leuk Lymphoma       Date:  2019-02-07

5.  Increasing Minority Enrollment Onto Clinical Trials: Practical Strategies and Challenges Emerge From the NRG Oncology Accrual Workshop.

Authors:  Sandra E Brooks; Carolyn Y Muller; William Robinson; Eleanor M Walker; Kate Yeager; Elise D Cook; Sue Friedman; Carol P Somkin; Carol Leslie Brown; Worta McCaskill-Stevens
Journal:  J Oncol Pract       Date:  2015-10-13       Impact factor: 3.840

6.  Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer.

Authors:  Shoshana M Rosenberg; Shari Gelber; Richard D Gelber; Ethan Krop; Larissa A Korde; Olivia Pagani; Ann H Partridge
Journal:  J Adolesc Young Adult Oncol       Date:  2017-07-07       Impact factor: 2.223

7.  Patient-Pivoted Automated Trial Eligibility Pipeline: The First of Three Phases in a Modular Architecture.

Authors:  Paul M Heider; Stéphane M Meystre
Journal:  Stud Health Technol Inform       Date:  2019-08-21

8.  Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program.

Authors:  Ryan D Nipp; Hang Lee; Elizabeth Powell; Nicole E Birrer; Emily Poles; Daniel Finkelstein; Karen Winkfield; Sanja Percac-Lima; Bruce Chabner; Beverly Moy
Journal:  Oncologist       Date:  2016-03-14

9.  Automatic trial eligibility surveillance based on unstructured clinical data.

Authors:  Stéphane M Meystre; Paul M Heider; Youngjun Kim; Daniel B Aruch; Carolyn D Britten
Journal:  Int J Med Inform       Date:  2019-05-23       Impact factor: 4.730

10.  Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community Oncologists.

Authors:  Andrew R Wong; Virginia Sun; Kevin George; Jennifer Liu; Simran Padam; Brandon A Chen; Thomas George; Arya Amini; Daneng Li; Mina S Sedrak
Journal:  JCO Oncol Pract       Date:  2020-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.